Hainan Huluwa Pharmaceutical Group Balance Sheet Health
Financial Health criteria checks 3/6
Hainan Huluwa Pharmaceutical Group has a total shareholder equity of CN¥1.2B and total debt of CN¥1.3B, which brings its debt-to-equity ratio to 110.4%. Its total assets and total liabilities are CN¥3.1B and CN¥1.9B respectively. Hainan Huluwa Pharmaceutical Group's EBIT is CN¥113.1M making its interest coverage ratio 10.2. It has cash and short-term investments of CN¥143.6M.
Key information
110.4%
Debt to equity ratio
CN¥1.32b
Debt
| Interest coverage ratio | 10.2x |
| Cash | CN¥143.61m |
| Equity | CN¥1.20b |
| Total liabilities | CN¥1.91b |
| Total assets | CN¥3.11b |
Recent financial health updates
Recent updates
We Think That There Are Issues Underlying Hainan Huluwa Pharmaceutical Group's (SHSE:605199) Earnings
Nov 06
Here's Why Hainan Huluwa Pharmaceutical Group (SHSE:605199) Has A Meaningful Debt Burden
Oct 23Hainan Huluwa Pharmaceutical Group Co., Ltd.'s (SHSE:605199) Shares Climb 27% But Its Business Is Yet to Catch Up
Sep 25There's Reason For Concern Over Hainan Huluwa Pharmaceutical Group Co., Ltd.'s (SHSE:605199) Massive 27% Price Jump
Sep 25Risks To Shareholder Returns Are Elevated At These Prices For Hainan Huluwa Pharmaceutical Group Co., Ltd. (SHSE:605199)
Jun 07Hainan Huluwa Pharmaceutical Group's (SHSE:605199) Shareholders Have More To Worry About Than Only Soft Earnings
May 03Financial Position Analysis
Short Term Liabilities: 605199's short term assets (CN¥1.3B) exceed its short term liabilities (CN¥1.2B).
Long Term Liabilities: 605199's short term assets (CN¥1.3B) exceed its long term liabilities (CN¥695.4M).
Debt to Equity History and Analysis
Debt Level: 605199's net debt to equity ratio (98.4%) is considered high.
Reducing Debt: 605199's debt to equity ratio has increased from 20.2% to 110.4% over the past 5 years.
Debt Coverage: 605199's debt is not well covered by operating cash flow (5.9%).
Interest Coverage: 605199's interest payments on its debt are well covered by EBIT (10.2x coverage).